DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the NOVARTIS INDIA LIMITED (NOVARTIND) share price today?

NOVARTIS INDIA LIMITED (NOVARTIND) is trading at ₹1,570.1 on the NSE, down 1.64% on the day. Source: DocStoX.

What is the PE ratio of NOVARTIS INDIA LIMITED?

NOVARTIS INDIA LIMITED has a price-to-earnings (PE) ratio of 38.4 in the Healthcare sector.

What is the market capitalisation of NOVARTIS INDIA LIMITED?

NOVARTIS INDIA LIMITED has a market capitalisation of approximately ₹3,880 crore.

NOVARTIS INDIA LIMITED

NOVARTIND·NSE·Healthcare

₹1,570.10▼ -26.10 (-1.64%)

Healthcare · Pharmaceuticals

Revenue under pressure recently

Day₹1532.60

₹1596.50

52W₹672

₹172385%

Open

₹1596.00

High

₹1596.50

Low

₹1532.60

Prev Close

₹1596.20

Volume

25.1K

VWAP

₹1556.46

Snapshot

Key fundamentals

Market Cap

₹3,880 Cr

P/E Ratio

38.42Expensive

P/B Ratio

4.41

EPS

₹40.87

Book Value

₹331.23

ROE

12.85%Average

ROCE

17.00%Decent

Dividend Yield

1.70%

Debt / Equity

0.00Low

Face Value

₹5.00

52W High

₹1723.00

52W Low

₹672.25

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹384

▼ 75.6%downside

Trading at ₹1,570 — 76% above our estimate

BearFair valueBull

₹326₹384₹552

/100

Business quality — Watch the fundamentals

Growth 0Profitability 70Efficiency 23Valuation 64

Plain English

Our view

Revenue under pressure recently
Virtually debt-free balance sheet
Revenue has been shrinking

Strengths

Virtually debt-free balance sheet
Promoters hold a controlling stake

Risks

Revenue has been shrinking
Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

13% ROE fading to 12% over ~3 yrs, on ₹331 book

₹337

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹552

Analyst target

No analyst coverage

—

Blended fair value₹384

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Promoters hold a controlling stake

Bear case

Revenue has been shrinking
Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

38.4Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

12.8%Average

Above 15% is considered healthy for Indian equities

ROCE

17.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹3,880 Cr

P/B

4.41

EPS

₹40.87

Div Yield

1.70%

What changed

Recent changes

Domestic institutions-0.1% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 38.4×

Growth

Shrinking

-2% rev CAGR

Profitability

Healthy

12.8% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %43.8%

Turnover₹391.25L Cr

Trades3,205

VWAP₹1556.46

Face value₹5.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

-2.2%

-1.4%

10Y

-6.5%

Profit

-3.3%

+34.7%

10Y

-7.3%

EPS

—

10Y

—

Profile

Pros

Company has reduced debt.
Company is almost debt free.

Watch-outs

Cons

The company has delivered a poor sales growth of -1.46% over past five years.
Company has a low return on equity of 11.9% over last 3 years.
Earnings include an other income of Rs.38.8 Cr.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Domestic institutions reduced 0.11 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

71%

Promoter

Promoters

70.7%0.00

Public

23.3%+0.58

FII / FPI

0.2%-0.02

DII

0.5%-0.11

Others

5.4%

Total shareholders

38,116-1,352 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter70.68%

FII0.17%

DII0.53%

Public23.25%

Others5.37%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods. [1] It imports various medicines to India from different sources across the globe.[2]